A Phase I, Open-Label, Single Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of PD-0332334 In Subjects Receiving Chronic Hemodialysis.
Phase of Trial: Phase I
Latest Information Update: 30 Oct 2009
At a glance
- Drugs Imagabalin (Primary)
- Indications Generalised anxiety disorder
- Focus Pharmacokinetics
- Sponsors Pfizer
- 30 Oct 2009 Actual initiation date changed from Oct 2008 to Sep 2008 as reported by ClinicalTrials.gov.
- 16 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jan 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.